<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04395807</url>
  </required_header>
  <id_info>
    <org_study_id>COVID HELMET</org_study_id>
    <nct_id>NCT04395807</nct_id>
  </id_info>
  <brief_title>Helmet CPAP Versus HFNC in COVID-19</brief_title>
  <acronym>COVID HELMET</acronym>
  <official_title>Helmet Continuous Positive Airway Pressure Versus High-Flow Nasal Cannula in COVID-19: A Pragmatic Randomised Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lund University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Region Skane</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lund University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      We aim to investigate whether the use of Continuous Positive Airway Pressure using a Helmet&#xD;
      device (Helmet CPAP) will increase the number of days alive and free of ventilator within 28&#xD;
      days compared to the use of a High Flow Nasal Cannula (HFNC) in patients admitted to&#xD;
      Helsingborg Hospital, Sweden, suffering from COVID-19 and an acute hypoxic respiratory&#xD;
      failure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A detailed description can be found in the study protocol published in Trials in Dec 2020:&#xD;
&#xD;
      Tverring, J., Åkesson, A. &amp; Nielsen, N. Helmet continuous positive airway pressure versus&#xD;
      high-flow nasal cannula in COVID-19: a pragmatic randomised clinical trial (COVID HELMET).&#xD;
      Trials 21, 994 (2020). https://doi.org/10.1186/s13063-020-04863-5&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    1. Few eligible patients at study start&#xD;
&#xD;
      2. Patients received HFNC prior to intermediate care ward admission&#xD;
&#xD;
      3. NIV was locally considered a step-up therapy to HFNC&#xD;
&#xD;
      4. Full-face masks replaced the Helmet interface as local NIV standard&#xD;
  </why_stopped>
  <start_date type="Actual">June 3, 2020</start_date>
  <completion_date type="Actual">April 12, 2021</completion_date>
  <primary_completion_date type="Actual">April 12, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ventilator-Free Days (VFD)</measure>
    <time_frame>28 days</time_frame>
    <description>Number of days alive and free of mechanical ventilation within 28 days. Patients who die within 28 days will be counted as 0 VFD. Time in ventilator will be counted in hours and rounded to whole days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SpO2/FiO2-ratio</measure>
    <time_frame>1 hour after randomisation</time_frame>
    <description>Peripheral oxygen saturation divided by fraction of inspired oxygen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient comfort</measure>
    <time_frame>24 hours after randomisation</time_frame>
    <description>Visual scale (1-10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of endotracheal intubation</measure>
    <time_frame>28 days</time_frame>
    <description>Min 0, Max 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of carbon dioxide rebreathing</measure>
    <time_frame>28 days</time_frame>
    <description>Defined as pCO2 &gt; 6 kPa in a venous blood gas. Min 0, Max ∞</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days alive within</measure>
    <time_frame>28 days and 180 days</time_frame>
    <description>All-cause mortality. (180 days endpoint not in primary publication)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>COVID</condition>
  <condition>Acute Hypoxemic Respiratory Failure</condition>
  <arm_group>
    <arm_group_label>Helmet CPAP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Helmet Continuous Positive Airway Pressure (CaStar hood for CPAP therapy by Starmed/Intersurgical) driven by high-flow blender (Bio-Med Devices).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HFNC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>High-Flow Nasal Cannula (OptiflowTM nasal high-flow interface) driven by AIRVO 2 humidification system (Fisher and Paykel)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Helmet CPAP</intervention_name>
    <description>Start-up air flow 40 L/min. Start-up PEEP 5 cmH2O. Max PEEP 20 cmH2O. Oxygen flow / FiO2% according to 92% SpO2 target. Titrations at physician's choice.</description>
    <arm_group_label>Helmet CPAP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HFNC</intervention_name>
    <description>Start-up air flow 30 L/min. Max air flow 60 L/min. Oxygen flow / FiO2% according to 92% SpO2 target. Titrations at physician's choice.</description>
    <arm_group_label>HFNC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (all of the following):&#xD;
&#xD;
          1. Age ≥ 18 years&#xD;
&#xD;
          2. Sars-Cov-2 found in the upper or lower respiratory tract by PCR during the current&#xD;
             disease episode&#xD;
&#xD;
          3. Peripheral oxygen saturation (SpO2) &lt; 92 % despite conventional low-flow oxygen&#xD;
             therapy of at least 6 L /min for at least 15 min&#xD;
&#xD;
          4. A decision to initiate HFNC or Helmet CPAP by the attending ward physician&#xD;
&#xD;
          5. The patient has given written informed consent to participate.&#xD;
&#xD;
        Exclusion Criteria (any of the following):&#xD;
&#xD;
          1. Need for direct admission to the intensive care unit for mechanical ventilation&#xD;
&#xD;
          2. Unconsciousness or drowsiness&#xD;
&#xD;
          3. Pneumothorax&#xD;
&#xD;
          4. Carbon dioxide pressure (pCO2) &gt; 6 kPa in venous blood gas (VBG)&#xD;
&#xD;
          5. Underlying chronic obstructive pulmonary disease stage III-IV&#xD;
&#xD;
          6. A decision not to participate&#xD;
&#xD;
          7. Inability to comprehend the study content and give informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonas Tverring, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lund University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Helsingborg's Hospital</name>
      <address>
        <city>Helsingborg</city>
        <state>Region Skane</state>
        <zip>252 23</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>May 18, 2020</study_first_submitted>
  <study_first_submitted_qc>May 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2020</study_first_posted>
  <last_update_submitted>April 12, 2021</last_update_submitted>
  <last_update_submitted_qc>April 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

